FORMULATION AND EVALUATION SUSTAINED RELEASE TABLET OF RABEPRAZOLE

V. Shirisha [1*], B. Manjula[1], Ramya Sri.S[2]

[1]Department of Pharmaceutics, Avanthi Institute of Pharmaceutical Sciences, Hyd, Telangana, India

[2]Department of Pharmaceutics, University College of Technology, Osmania University, Hyderabad, Telangana, India

***Corresponding Author**

V. Shirisha
Department of Pharmaceutics,
Avanthi Institute of Pharmaceutical Sciences,
Hyd, Telangana, India.
Email Id- surapharmalabs@gmail.com

ABSTRACT

The main aim of present work was to formulate and evaluate sustain release matrix tablets of Rabeprazole is an Anti-Ulcer agent. Sustain release formulation are those which delivers the drug locally or systemically at a predetermined rate for a fixed period of time. The matrix tablet was prepared by direct compression method using by various concentration of Sodium Alginate and Eudragit RLPO various release retardant polymer. The powder mixtures were subjected to various pre-compression parameters such as angle of repose, bulk density, tapped density and Carr's index shows satisfactory result and the compressed tablets are evaluated for post-compression parameters such as weight variation, thickness, hardness, friability, drug content, *in-vitro* dissolution studies. *In-vitro* dissolution studies were carried out for 12 hours using 0.1 N HCL for first 2 hours and pH 6.8 phosphate buffer for 12 hours and the result showed that formulations F5 showed good dissolution profile to control the drug release respectively. Formulation containing lower concentration of Eudragit RLPO polymer sustained the drug release for the period of 12 hours. The kinetics studies the optimized formulation followed Zero order release kinetics.

Key words: Rabeprazole, Sodium Alginate, Eudragit RLPO, Direct compression and Sustained release matrix tablets.

INTRODUCTION

Administration of drugs, which is due in part to the ease of administration and to the fact that gastrointestinal physiology offers more flexibility in dosage form design than most other routes. The terms Sustained release, prolonged release, modified release, extended release or depot formulations are used to identify drug delivery systems that are designed to achieve or extend therapeutic effect by continuously releasing medication over an extended period of time after administration of a single dose. The advantages of administering a single dose of a drug that is released over an extended period of time, instead of numerous doses, have been obvious to the Pharmaceutical industry for some time. The desire to maintain a near constant or uniform blood level of a drug often translates into better patient compliance, as well as enhanced clinical efficacy of the drug for its intended use. Because of increased complication and expense involved in marketing of new drug entities, has focused greater attention on development of sustained or controlled release drug delivery systems. Matrix system is widely used for the purpose of sustained release. It is the release system which prolongs and controls the release of the drug that is dissolved or dispersed. In fact, a matrix is defined as a well-mixed composite of one or more drugs with gelling agent i.e. hydrophilic polymers. The goal of an extended release dosage form is to maintain therapeutic drug level in plasma for extended period of time.[1]

Now a day's conventional dosage forms of drugs are rapidly being replaced by the new and the novel drug delivery systems. Amongst, these the controlled release/sustained release dosage forms have become extremely popular in modern therapeutics. Matrix system is the release system which prolongs and controls the release of the drug, which is dissolved or dispersed. A matrix is defined as a well-mixed composite of one or more drugs with gelling agent i.e. hydrophilic polymers. Introduction of matrix tablet as sustained release (SR) has given a new breakthrough for novel drug delivery system in the field of Pharmaceutical technology. Sustained release constitutes any dosage form that provides medication over an extended time or denotes that the system is able to provide some actual therapeutic control whether this is of a temporal nature, spatial nature or both. Sustained release system generally do not attain zero order type release and usually try to mimic zero order release by providing drug in a slow first order. Repeat action tablet are an alternative method of sustained release in which multiple doses

of drug are an alternative method of sustained release, in which, multiple doses are contained within a dosage form and each dose is released at a periodic interval.[2]

The goal in designing sustained or sustained delivery systems is to reduce the frequency of the dosing or to increase effectiveness of the drug by localization at the site of action, reducing the dose required or providing uniform drug delivery. So, sustained release (SR) dosage form is a dosage form that release one or more drugs continuously in a predetermined pattern for a fixed period of time, either systemically or to a specified target organ. The goal of an SR dosage form is to maintain therapeutic blood or tissue levels of the drug for an extended period. This is usually accomplished by attempting to obtained zero-order release from the dosage form. Zero-order release constitutes drug release from the dosage form that is independent of the amount of drug in the delivery system (i.e., a constant release rate). SR systems generally do not attain this type of release and usually try to mimic zero-order release by providing the drug in a slow first-order fashion (i.e., concentration dependent).[3]

MATERILAS AND METHODS

Rabeprazole Provided by SURA LABS, Dilsukhnagar, Hyderabad. Sodium Alginate from Merck Specialities Pvt Ltd, Mumbai, India. Eudragit RLPO from Merck Specialities Pvt Ltd, Mumbai, India. Lactose from Merck Specialities Pvt Ltd, Mumbai, India. Magnesium stearate from Merck Specialities Pvt Ltd, Mumbai, India. Talc from Merck Specialities Pvt Ltd, Mumbai, India.

METHODOLOGY

Analytical method development:

Buffer Preparation:

Preparation of 0.2 M Potassium dihydrogen orthophosphate solution: Accurately weighed 27.218 gm of monobasic potassium dihydrogen orthophosphate was dissolved in 1000mL of distilled water and mixed.

Preparation of 0.2M sodium hydroxide solution: Accurately weighed 8 gm sodium hydroxide pellets were dissolved 1000ml of distilled water and mixed.

Preparation of pH 6.8 Phosphate buffer: Accurately measured 250ml of 0.2M potassium Dihydrogen ortho phosphate and 112.5 ml 0.2M NaOH was taken into the 1000ml volumetric flask. Volume was made up to 1000ml with distilled water.

Determination of Wavelength:

10mg of pure drug was dissolved in 10ml methanol (primary stock solution - 1000 µg/ml). From this primary stock solution 1 ml was pipette out into 10 ml volumetric flask and made it up to 10ml with the media (Secondary stock solution – 100µg/ml). From secondary stock solution again 1ml was taken it in to another volumetric flask and made it up to 10 ml with media (working solution - 10µg/ml). The working solution was taken for determining the wavelength.

Determination of Calibration Curve:

10mg of pure drug was dissolved in 10ml methanol (primary stock solution - 1000 µg/ml). From this primary stock solution 1 ml was pipette out into 10 ml volumetric flask and made it up to 10ml with the media (Secondary stock solution – 100µg/ml). From secondary stock solution required concentrations were prepared (shown in Table 2 and 3) and those concentrations absorbance were found out at required wavelength.

Preformulation parameters

The quality of tablet, once formulated by rule, is generally dictated by the quality of physicochemical properties of blends. There are many formulations and process variables involved in mixing and all these can affect the characteristics of blends produced. The various characteristics of blends tested as per Pharmacopoeia.

Formulation development of tablets:

All the formulations were prepared by direct compression. The compositions of different formulations are given in Table 1. The tablets were prepared as per the procedure given below and aim is to prolong the release of Rabeprazole. Total weight of the tablet was considered as 150mg.

Procedure:

1) Rabeprazole and all other ingredients were individually passed through sieve no ≠ 60.
2) All the ingredients were mixed thoroughly by triturating up to 15 min.
3) The powder mixture was lubricated with talc.
4) The tablets were prepared by using direct compression method.

Table 1: Formulation composition for tablets

INGREDIENTS (mg)	FORMULATION CODE							
	F1	**F2**	**F3**	**F4**	**F5**	**F6**	**F7**	**F8**
Rabeprazole	20	20	20	20	20	20	20	20
Sodium Alginate	20	40	60	80	-	-	-	-
Eudragit RLPO	-	-	-	-	20	40	60	80
Lactose	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S
Magnesium stearate	5	5	5	5	5	5	5	5
Talc	3	3	3	3	3	3	3	3
Total Weight	150	150	150	150	150	150	150	150

All the quantities were in mg

RESULTS & DISCUSSION

The present study was aimed to developing sustained release tablets of Rabeprazole using various polymers. All the formulations were evaluated for physicochemical properties and *in vitro* drug release studies.

Analytical Method

Graphs of Rabeprazole were taken in 0.1N HCL and in pH 6.8 phosphate buffer at 244 nm and 247 nm respectively.

Table 2: Observations for graph of Rabeprazole in 0.1N HCL

Concentration (µg/ml)	Absorbance
0	0
2	0.127
4	0.243
6	0.341
8	0.467
10	0.568



Fig 1: Standard curve of Rabeprazole

Table 3: Standard graph values of Rabeprazole at 247 nm in pH 6.8 phosphate buffer

Concentration (µg/ml)	Absorbance
0	0
2	0.113
4	0.221
6	0.315
8	0.421
10	0.531



Fig 2: Standard curve of Rabeprazole

Preformulation parameters of powder blend

Table 4: Pre-formulation parameters of Core blend

Formulation Code	Angle of Repose	Bulk density (gm/mL)	Tapped density (gm/mL)	Carr's index (%)	Hausner's Ratio
F1	29.5 ± 0.11	0.47 ± 0.11	0.56 ± 0.05	16.4 ± 0.13	1.15 ± 0.13
F2	34.0 ± 0.05	0.51 ± 0.08	0.64 ± 0.03	21.4 ± 0.14	1.23 ± 0.06

F3	40.4 ± 0.03	0.50 ± 0.09	0.62 ± 0.02	21.3 ± 0.07	1.26 ± 0.07
F4	33.8 ± 0.12	0.51 ± 0.08	0.63 ± 0.09	20.5 ± 0.05	1.24 ± 0.12
F5	31.2 ± 0.10	0.49 ± 0.05	0.60 ± 0.06	19.7 ± 0.11	1.24 ± 0.07
F6	35.5 ± 0.07	0.50 ± 0.08	0.62 ± 0.07	19.1 ± 0.07	1.20 ± 0.14
F7	30.8 ± 0.04	0.49 ± 0.07	0.60 ± 0.04	20.3 ± 0.05	1.23 ± 0.12
F8	28.2 ± 0.06	0.50 ± 0.09	0.60 ± 0.06	18.4 ± 0.12	1.14 ± 0.06

All the values represent n=3

Tablet powder blend was subjected to various pre-formulation parameters. The angle of repose values indicates that the powder blend has good flow properties. The bulk density of all the formulations was found to be in the range of 0.47 ± 0.11 to 0.51 ± 0.08 (gm/ml) showing that the powder has good flow properties. The tapped density of all the formulations was found to be in the range of 0.56 ± 0.05 to 0.64 ± 0.03 showing the powder has good flow properties. The compressibility index of all the formulations was found to be below 21.4 which show that the powder has good flow properties. All the formulations has shown the hausners ratio ranging between 1.14 to 1.26 indicating the powder has good flow properties.

Quality control parameters for tablets:

Tablet quality control tests such as weight variation, hardness, friability, thickness, and drug release studies in different media were performed on the compressed tablet.

Table 5: *In vitro* quality control parameters for tablets

Formulation codes	Weight variation (mg)	Hardness (kg/cm^2)	Friability (%loss)	Thickness (mm)	Drug content (%)
F1	149.52	4.6	0.51	2.16	98.31
F2	150.12	4.1	0.42	2.95	99.09
F3	148.91	4.0	0.38	2.11	98.19

F4	150.01	4.8	0.43	2.76	97.60
F5	150.09	4.6	0.38	2.43	99.43
F6	149.87	4.9	0.29	2.68	98.14
F7	148.35	4.5	0.50	2.90	97.34
F8	149.29	4.3	0.46	2.59	99.62
F9	150.21	4.7	0.35	2.60	98.46

Weight variation test:

Tablets of each batch were subjected to weight variation test, difference in weight and percent deviation was calculated for each tablet. The average weight of the tablet is approximately in range of 148.35 to 150.21 mg, so the permissible limit is ±7.5% (>150 mg). The results of the test showed that, the tablet weights were within the pharmacopoeia limit.

Hardness test:

Hardness of the three tablets of each batch was checked by using Pfizer hardness tester and the data's were shown in Table 5. The results showed that the hardness of the tablets is in range of 4.0 to 4.9 kg/cm^2, which was within IP limits.

Thickness:

Thickness of three tablets of each batch was checked by using Micrometer and data shown in Table-5. The result showed that thickness of the tablet is raging from 2.11 to 2.95 mm.

Friability:

Tablets of each batch were evaluated for percentage friability and the data were shown in the Table 5. The average friability of all the formulations was less than 1% as per official requirement of IP indicating a good mechanical resistance of tablets.

Drug content:

Drug content studies were performed for the prepared formulations. From the drug content studies it was concluded that all the formulations were showing the % drug content values within 97.34 -99.62 %.

All the parameters such as weight variation, friability, hardness, thickness and drug content were found to be within limits.

***In Vitro* Drug Release Studies**

Table 6: Dissolution data of Rabeprazole tablets

TIME (H)	F1	F2	F3	F4	F5	F6	F7	F8
0	0	0	0	0	0	0	0	0
1	15.80	12.38	08.72	05.48	14.99	13.81	10.93	08.38
2	21.63	16.14	15.20	10.15	20.53	18.96	16.15	11.69
3	28.12	20.72	21.63	17.86	27.60	26.71	20.68	18.19
4	32.90	27.95	28.95	24.32	33.12	35.56	27.14	24.43
5	39.17	34.14	35.17	30.91	36.24	40.12	34.39	29.37
6	46.05	40.73	39.85	36.15	40.71	43.90	38.71	35.65
7	50.34	47.90	45.36	41.63	47.68	51.18	42.52	40.97
8	67.29	55.12	52.21	45.27	55.92	57.21	48.10	48.21
9	71.76	60.47	60.74	56.14	69.15	62.19	54.98	52.10
10	82.39	74.50	66.85	60.70	72.76	68.11	57.71	57.78

11	90.12	82.09	73.92	66.14	88.40	86.07	67.50	65.86
12	96.21	87.11	78.17	71.56	98.62	92.46	77.86	70.15



Fig 3: Dissolution profile of Rabeprazole (F1, F2, F3 and F4 formulations)



Fig 4: Dissolution profile of Rabeprazole (F5, F6, F7 and F8 formulations)

From the dissolution data it was evident that the formulations prepared with Sodium Alginate as polymer were retarded the drug release more than 12 hours.

Whereas the formulations prepared with Eudragit RLPO retarded the drug release up to 12 hours in the concentration 20 mg. In higher concentrations the polymer was unable to retarded the drug release.

Hence from the above dissolution data it was concluded that F5 formulation was considered as optimised formulation because good drug release (98.62%) in 12 hours.

Application of release rate kinetics to dissolution data

Data of *in vitro* release studies of formulations which were showing better drug release were fit into different equations to explain the release kinetics of Rabeprazole release from Sustained tablets. The data was fitted into various kinetic models such as zero, first order kinetics; higuchi and korsmeyer peppas mechanisms and the results were shown in below table.

Table 7: Release kinetics data for optimized formulation (F5)

CUMULATIVE (%) RELEASE Q	TIME (T)	ROOT (T)	LOG(%) RELEASE	LOG (T)	LOG (%) REMAIN	RELEASE RATE (CUMULATIVE % RELEASE / t)	1/CUM% RELEASE	PEPPAS log Q/100	% Drug Remaining	Q01/3	Qt1/3	Q01/3-Qt1/3
0	0	0			2.000				100	4.642	4.642	0.000
14.99	1	1.000	1.176	0.000	1.929	14.990	0.0667	-0.824	85.01	4.642	4.397	0.245
20.53	2	1.414	1.312	0.301	1.900	10.265	0.0487	-0.688	79.47	4.642	4.299	0.342
27.6	3	1.732	1.441	0.477	1.860	9.200	0.0362	-0.559	72.4	4.642	4.168	0.474
33.12	4	2.000	1.520	0.602	1.825	8.280	0.0302	-0.480	66.88	4.642	4.059	0.582
36.24	5	2.236	1.559	0.699	1.805	7.248	0.0276	-0.441	63.76	4.642	3.995	0.647
40.71	6	2.449	1.610	0.778	1.773	6.785	0.0246	-0.390	59.29	4.642	3.899	0.742
47.68	7	2.646	1.678	0.845	1.719	6.811	0.0210	-0.322	52.32	4.642	3.740	0.901
55.92	8	2.828	1.748	0.903	1.644	6.990	0.0179	-0.252	44.08	4.642	3.532	1.109
69.15	9	3.000	1.840	0.954	1.489	7.683	0.0145	-0.160	30.85	4.642	3.136	1.505
72.76	10	3.162	1.862	1.000	1.435	7.276	0.0137	-0.138	27.24	4.642	3.009	1.633
88.4	11	3.317	1.946	1.041	1.064	8.036	0.0113	-0.054	11.6	4.642	2.264	2.378
98.62	12	3.464	1.994	1.079	0.140	8.218	0.0101	-0.006	1.38	4.642	1.113	3.528



Figure 5: Graph of zero order kinetics

Based on the data above results the optimized formulation followed Zero order kinetics.

Drug and excipient compatibility studies

FTIR STUDY



Fig. 6: FTIR Graph of pure drug



Fig 7: FTIR Graph of Optimised Formulation

From the FTIR data it was evident that the drug and excipients does not have any interactions. Hence they were compatible.

CONCLUSION:

The oral route of drug delivery is the most preferred route for administration of drugs. The rationale for the development of a sustained release formulation of a drug is to enhance its therapeutic benefits, minimizing its side effect while improving the management of the diseased condition. Sustained drug delivery systems significantly improve the therapeutic efficacy of drugs. Drug-release-retarding polymers are the key performers in such systems.

Rabeprazole is a medication that decreases stomach acid. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and excess stomach acid production such as in Zollinger–Ellison syndrome. It may also be used in combination with other medications to treat Helicobacter pylori. Rabeprazole has a half-life of 1hours.

FT-IR frequencies showed that the Rabeprazole used was similar to the reported values. After the comparison of FTIR results, it was concluded that there was no incompatibility between drug and polymers. Polymers like Sodium Alginate and Eudragit RLPO were chosen as polymers for the formation of sustained release matrix tablets.

In this study, nine formulations were prepared by direct compression method using different polymers at varying ratios.

Each batch of the formulations was evaluated for pre-compression parameters such as bulk density, tapped density, the angle of repose, compressibility index and Hausner's ratio and the results were within the limit. The prepared formulations were also evaluated for hardness, friability, weight variation, content uniformity and *in-vitro* drug release studies.

Formulation F5 showed sustained drug release for 12 hours so it was selected as the best formulation among all the nine formulations. The kinetics of drug release was best explained by Zero order kinetics

Based on the above evaluation studies, it could be concluded that taken polymers can be used as a suitable matrix forming agent by direct compression method for sustained release of Rabeprazole over 12 hr by providing reduced dosing frequency and side effects.

REFERENCES

1. N. G. Raghavendra Rao, K. Richard Prasanna Raj, B. Sanjeev Nayak. Review on Matrix Tablet as Sustained Release. Volume 2, Issue 3 (2013),1-17.
   2. Tarun Parashar,Soniya, Vishal Singh, Gaurav Singh, Satyanand Tyagi, Chirag Patel, Anil Gupta. Novel Oral Sustained Release Technology: A Concise Review.
2. Sudhir Karna, Shashank Chaturvedi, Vipin Agrawal, Mohammad Alim. Formulation Approaches For Sustained Release Dosage Forms: A Review. Asian J Pharm Clin Res, Vol 8, Issue 5, 2015, 46-53.
3. C.nithya shanthi, rakesh gupta, arun kumar mahato. A review on captopril oral sustained/controlled release Formulations. Int.J.Drug Dev. & Res., April-June 2010, 2(2): 257-267.
4. Rakesh Roshan Mali, Vaishali Goel, Sparsh Gupta. Novel Study in Sustained Release Drug Delivery System: A Review. Int. J. Pharm. Med. Res. 2015; 3(2):204-215.
5. Abhijeet Welankiwar. Review: Sustained Release Dosage Forms .
6. Lilesh khalane, atul alkunte, arunadevi birajdar. Sustained Release Drug Delivery System : A Concise Review.
7. Piyush Mandhar , Gayitri Joshi. Development of Sustained Release Drug Delivery System: A Review. Asian Pac. J. Health Sci., 2015; 2(1): 179-185.

8. H.D.Zalte, R.B.Saudagar. Review On Sustained Release Matrix Tablet. IJPBS -Volume 3- Issue 4 -OCT-DEC-2013-17-29.
9. Heena Farooqui and Prashant Upadhyay. Formulation And Evaluation Of Sustained-Release Tablet Having Genistein. IJPSR, 2022; Vol. 13(2): 810-820.
10. Lateef Gbenga Bakre, Emmanuel Akinyele, Oluyemisi Bamiro, Olutayo Adeleye, Olobayo Kunle. Formulation and Evaluation of Sustained Release Ibuprofen Matrix Tablets Using Starch from Maize Genotypes as Polymer. Seria Medica 2021;67(2):122-126.
11. D. Nagasamy Venkatesh, S. N. Meyyanathan, A. Mohamed Sheik Tharik, Srinivas Rao. Formulation and Evaluation of sustained release tablets of Ramipril. Research J. Pharm. and Tech. 2020; 13(8):3873-3878.